prednisone has been researched along with vasoactive intestinal peptide in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (50.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Cooperman, AM; Desantis, D; Eversman, J; Farmer, R; Said, S; Winkelman, E | 1 |
Joehl, RJ; Koch, KL; O'Dorisio, TM; Pokorney, B; Weinstein, GS | 1 |
Bousquet, J; Chanez, P; Godard, P; Moradoghi-Hattvani, A; Polak, JM; Springall, D; Vignola, AM | 1 |
Chen, X; He, H; Huang, Z; Lang, H; Wang, J; Yan, X; Zhang, Y; Zhao, Q | 1 |
4 other study(ies) available for prednisone and vasoactive intestinal peptide
Article | Year |
---|---|
Watery diarrhea syndrome. Two unusual cases and further evidence that VIP is a humoral mediator.
Topics: Adenoma, Islet Cell; Adrenal Gland Neoplasms; Aged; Diarrhea; Female; Gastrointestinal Hormones; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pheochromocytoma; Prednisone; Vasoactive Intestinal Peptide | 1978 |
Exacerbation of diarrhea after iodinated contrast agents in a patient with VIPoma.
Topics: Adenoma, Islet Cell; Contrast Media; Diarrhea; Diatrizoate; Humans; Iodine; Iopanoic Acid; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Prednisone; Vasoactive Intestinal Peptide; Vipoma | 1985 |
Bronchial mucosal immunoreactivity of sensory neuropeptides in severe airway diseases.
Topics: Administration, Oral; Adolescent; Adult; Aged; Asthma; Beclomethasone; Biomarkers; Biopsy; Bronchi; Bronchitis; Bronchoconstriction; Calcitonin Gene-Related Peptide; Capillary Permeability; Chronic Disease; Epithelium; Female; Fluorescent Antibody Technique, Direct; Glucocorticoids; Humans; Male; Middle Aged; Mucous Membrane; Muscle, Smooth; Nerve Tissue Proteins; Neuropeptide Y; Neuropeptides; Prednisone; Substance P; Thiolester Hydrolases; Ubiquitin Thiolesterase; Vasoactive Intestinal Peptide; Vasomotor System | 1998 |
Research on the mechanism of prednisone in the treatment of ITP via VIP/PACAP-mediated intestinal immune dysfunction.
Topics: Animals; Cytokines; Interleukin-10; Interleukin-17; Interleukin-4; Mice; Pituitary Adenylate Cyclase-Activating Polypeptide; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Receptors, Vasoactive Intestinal Peptide; Tumor Suppressor Protein p53; Vasoactive Intestinal Peptide | 2023 |